Physician profile
Robert J Masters
NPI 1164402996
$7,516.99
in general payments reported to CMS, 2019-2025
29 companies · $925 in 2025
The $925 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $986 · 2022: $1,647 · 2023: $1,673 · 2024: $2,286 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,788 · Education: $95.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,788.39 |
| Education | $95.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,910.56 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $636.06 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $631.20 | 2021-2025 | Tremfya |
| Leo Pharma INC. | $572.06 | 2021-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $568.81 | 2022-2025 | Sotyktu |
| Ucb, INC. | $426.17 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $407.10 | 2023-2025 | Otezla, Otezla, Enbrel |
| Pfizer INC. | $405.31 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $383.49 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $253.12 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Galderma Laboratories, L.P. | $241.52 | 2021-2025 | Nemluvio, Epsolay, Aklief |
| Incyte Corporation | $199.77 | 2021-2025 | Opzelura |
| Genzyme Corporation | $152.70 | 2021-2025 | |
| Lilly USA, LLC | $102.60 | 2021-2024 | Taltz, Olumiant |
| Organon LLC | $99.96 | 2023-2025 | Vtama, Hadlima |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $71.59 | 2022-2023 | Vtama |
| Arcutis Biotherapeutics, INC. | $58.92 | 2023-2024 | Zoryve |
| Epi Health, LLC | $57.66 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $48.69 | 2021 | |
| Genentech USA, INC. | $48.18 | 2021-2024 | Erivedge |
| Almirall LLC | $37.31 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $34.24 | 2021-2022 | |
| Mylan Institutional INC. | $32.45 | 2023 | Hulio |
| Biocon Biologics INC | $30.83 | 2023 | Hulio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.77 | 2023 | Spevigo |
| Blueprint Medicines Corporation | $26.56 | 2024 | Ayvakit |
| Biofrontera INC. | $20.04 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Sanofi-Aventis U.S. LLC | $17.54 | 2021 | |
| Genentech, INC. | $14.78 | 2023 | Erivedge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Masters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.